Beijing Strong BiotechnologiesInc マネジメント

マネジメント基準チェック /34

Beijing Strong BiotechnologiesIncの CEO はXi Liuで、 Mar2011年に任命され、の在任期間は 13.67年です。は、会社の株式の11.48%を直接所有しており、その価値はCN¥ 963.66M 。経営陣と取締役会の平均在任期間はそれぞれ13.7年と5.9年です。

主要情報

Xi Liu

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	13.7yrs
CEOの所有権	11.5%
経営陣の平均在職期間	13.7yrs
取締役会の平均在任期間	5.9yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Xi Liu (62 yo)

13.7yrs

在職期間

CN¥2,434,400

報酬

Mr. Xi Liu has been General Manager and Non-Independent Director of Beijing Strong Biotechnologies, Inc. since March 2011. Mr. Liu holds Ph.D.

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Xi Liu	GM & Non-Independent Director	13.7yrs	CN¥2.43m	11.48% CN¥ 963.7m
Wei Liu	CFO & Accounting Supervisor	13.7yrs	CN¥574.90k	0.027% CN¥ 2.2m
Sheng Dan	Deputy GM & Non-Independent Director	no data	CN¥1.81m	0.061% CN¥ 5.1m
Jian Min Wang	Secretary of the Board of Directors	9.4yrs	CN¥472.80k	0.071% CN¥ 6.0m
Qinghai Yang	Deputy General Manager	no data	データなし	0.048% CN¥ 4.0m
Qixin Lin	Deputy General Manager	no data	データなし	0.054% CN¥ 4.5m

13.7yrs

平均在職期間

47.5yo

平均年齢

経験豊富な経営陣: 300406の経営陣は経験豊富で経験豊富です（平均在職期間は13.7年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Xi Liu	GM & Non-Independent Director	13.7yrs	CN¥2.43m	11.48% CN¥ 963.7m
Sheng Dan	Deputy GM & Non-Independent Director	4.3yrs	CN¥1.81m	0.061% CN¥ 5.1m
Zuojun Zou	Chairman of the Board	13.7yrs	CN¥2.43m	6.73% CN¥ 564.9m
Xiaolin Sun	Non-Independent Director	13.7yrs	データなし	8.63% CN¥ 724.6m
Aiping Luo	Non-Independent Director	13.7yrs	データなし	9.76% CN¥ 819.3m
Tao Jiang	Chairman of the Supervisory Committee	7.6yrs	CN¥84.00k	データなし
Jian Ding	Independent Director	no data	CN¥84.00k	データなし
Lei Fu	Independent Director	no data	CN¥84.00k	データなし
Yonghong Chen	Independent Director	4.3yrs	CN¥84.00k	データなし
Hongjun Liang	Non-Independent Director	4.3yrs	データなし	データなし
Xiaoya Wang	Non-Independent Director	1.2yrs	データなし	0.080% CN¥ 6.7m
Jianping Yang	Independent Director	1.2yrs	データなし	データなし

5.9yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: 300406の取締役会は経験豊富であると考えられます ( 5.9年の平均在任期間)。

Beijing Strong BiotechnologiesInc マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Beijing Strong Biotechnologies,Inc., Annual General Meeting, Apr 22, 2024

Beijing Strong Biotechnologies,Inc. Approves Executive Appointments

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.22 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Beijing Strong Biotechnologies,Inc. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 2Q 2023)

Beijing Strong Biotechnologies,Inc. to Report First Half, 2024 Results on Aug 23, 2024

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.19 in 1Q 2023)

Upcoming dividend of CN¥0.20 per share

Beijing Strong Biotechnologies,Inc. Announces Final Cash Dividend (Tax Included) (A Shares) for 2023, Payable on 07 May 2024

Full year 2023 earnings released: EPS: CN¥0.90 (vs CN¥0.67 in FY 2022)

Beijing Strong Biotechnologies,Inc., Annual General Meeting, Apr 22, 2024

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Beijing Strong Biotechnologies,Inc. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 3Q 2022)

Beijing Strong Biotechnologies,Inc. to Report Q3, 2023 Results on Oct 25, 2023

Beijing Strong Biotechnologies,Inc. Approves Executive Appointments

Insufficient new directors

Second quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.11 in 2Q 2022)

New minor risk - Dividend sustainability

Beijing Strong Biotechnologies, Inc. (SZSE:300406) announces an Equity Buyback for CNY 80 million worth of its shares.

Beijing Strong Biotechnologies, Inc. to Report First Half, 2023 Results on Aug 10, 2023

Beijing Strong Biotechnologies, Inc. Announces Dividend on Share A for 2022, Payable on May 22, 2023

Full year 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.69 in FY 2021)

Now 21% undervalued

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2021)

Beijing Strong Biotechnologies, Inc. (SZSE:300406) signed an Equity Transfer Agreement to acquire an additional 4.45% stake in Fuzhou Maixin Biotech. Co., Ltd. from Xinyu Yuanlang Management Consulting Partnership (Limited Partnership) for approximately CNY 130 million.

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.19 in 2Q 2021)

Beijing Strong Biotechnologies, Inc. Announces Final Dividend on A Shares for the Year 2021, Payable on 27 May 2022

Beijing Strong Biotechnologies, Inc. Approves Cash Dividend for 2021

Beijing Strong Biotechnologies, Inc. Announces Final Cash Dividend Proposal for 2021

Full year 2021 earnings released: EPS: CN¥0.69 (vs CN¥0.21 in FY 2020)

Beijing Strong Biotechnologies, Inc. (SZSE:300406) entered into an agreement to acquire 75% stake in Wuhan Healcare Pharmaceuticals Technology Development Co., Ltd. from Xia Zhihui and Wang Ying for CNY 4 million.

Investor sentiment improved over the past week

Beijing Strong Biotechnologies, Inc. (SZSE:300406) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.039 in 2Q 2020)

Beijing Strong Biotechnologies, Inc. Announces Final Cash Dividend for 2020, Payable on 27 May 2021

Full year 2020 earnings released: EPS CN¥0.21 (vs CN¥0.66 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.21 (vs CN¥0.66 in FY 2019)

New 90-day low: CN¥20.29

Beijing Strong Biotechnologies, Inc. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: CN¥23.45

Third quarter earnings released

New 90-day low - CN¥19.38

First half earnings released

Beijing Strong Biotechnologies, Inc. to Report First Half, 2020 Results on Aug 28, 2020

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34